Deutsche Stiftung Weltbevölkerung's (DSW) main feedback is as follows: 1. The EU pharmaceutical legislation should consider its potential impacts on global health, and explore ways to directly contribute to addressing the most urgent and complex global health challenges.
Deutsche Stiftung Weltbevölkerung
NGO · Belgium · EU Transparency Register 32018754890-28
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1106 non-governmental organisations on this site, they rank #330 by legislative files engaged, a count of participation, not a measure of influence.
Declares membership of
- DSW and the United Nations
- DSW is the German partner of UNFPA, the United Nations Population Fund. On behalf of the UNFPA, DSW annually releases…
- Countdown 2030 Europe
- Along with 14 other consortium partners, DSW is a member of Countdown 2030 Europe, a partnership of European SRH orga…
- VENRO, the Association of German Development non-Governmental Organisations (NGOs), is the umbrella organisation of i…
- The European NGO confederation for relief and development - DSW works quite closely with Concord Europe. CONCORD is t…
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Non-governmental organisations
- Registered as
- DSW (Deutsche Stiftung Weltbevoelkerung) (DSW)
- Head office
- Hannover, Germany
- EU office
- Bruxelles
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Deutsche in PolicySpeak: request access →
Work at Deutsche Stiftung Weltbevölkerung? so we know who speaks for it.
Their record over time
Deutsche Stiftung Weltbevölkerung filed 4 positions between 8 Nov 2023 and 29 Apr 2026, across 4 of the 665 legislative files tracked here, attaching a full position paper 4 times.
What they argued
As a stakeholder of the global health community working closely with researchers and product developers, DSW draws attention to 5 key points in the development of the European Biotech Act. As outlined in the Commissions 2024 Communication; biotechnology and its applications hold great promise in tackling societal challenges and driving EU competitiveness, including in the areas of health, which is the focus of this…
DSW INPUT: EU INNOVATION ACT CALL FOR EVIDENCE Draghis report identified health innovation as a priority for EU competitiveness, while President von der Leyens State of the Union address reaffirmed readiness to lead in global health. As a convener of the global health community working with academia, researchers, and product developers, DSW draws attention to four points for the Innovation Act.
The EU GAP IV must maintain the three core principles of GAPIII of intersectionality, a human-rights approach, and gender-transformative action, while addressing gaps in delivery and elevating its ambition. Stronger political visibility and accountability are needed to ensure measurable results.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Deutsche Stiftung Weltbevölkerung next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 101.
Is this your organization?
Everything on this page comes from Deutsche Stiftung Weltbevölkerung’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.